Month: April 2020

BELTSVILLE, Md., April 08, 2020 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 19th Annual Needham Virtual Healthcare Conference on April 15th at 2:10 pm Eastern time.A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available approximately two hours after the event and archived on the website for 30 days.About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary...

SALT LAKE CITY, April 08, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, announced today that due to the impact of the global COVID-19 pandemic, the company is withdrawing its fiscal year 2020 financial guidance.“Prior to mid-March we were experiencing volume trends consistent with our expectations across all products; however, recent social distancing guidelines have had a significant impact on test volume trends in late March and into the fiscal fourth-quarter,” said R. Bryan Riggsbee, interim president and CEO and chief financial officer at Myriad Genetics.  “Our priority as an organization during the coronavirus pandemic has been to maintain business continuity and access to testing, while ensuring the safety of our employees and customers. As an organization we have taken...

ALPHARETTA, Ga., April 08, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer and Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer will present a company overview at the Needham Virtual Healthcare Conference on April 15, 2020 at 12:00 p.m. ET.A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.About Clearside BiomedicalClearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing...

Recordati Rare Diseases is now the European Marketing Authorization holder of Isturisa® (osilodrostat) indicated for Adult patients with Endogenous Cushing’s Syndrome  Paris, 8 April, 2020 – Recordati Rare Diseases today announces the transfer of the European Marketing Authorization of Isturisa® (osilodrostat). The transfer includes all EU member states plus the UK, Norway, Iceland and Liechtenstein.Isturisa® is authorized for the treatment of adult patients with Cushing’s syndrome. Isturisa® is a potent inhibitor of 11β-­hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis1. Isturisa® has demonstrated rapid and sustained normalization of cortisol levels in a significant proportion of adult patients with a manageable safety profile, making this a novel oral treatment option for patients with Cushing’s...

MONTREAL and SARASOTA, Fla., April 08, 2020 (GLOBE NEWSWIRE) — Intertape Polymer Group Inc. (TSX:ITP) (“IPG” or the “Company”) today provided an update on its operations during the coronavirus COVID-19 (“COVID-19”) pandemic. The Company’s North American and European manufacturing operations are open and producing as a result of the essential nature of the end markets it serves.“Safety is our highest priority. As such, we are committed to ensuring a safe work environment for our employees, as well as their safety once they return home to their family,” said Greg Yull, President and CEO of IPG. “Our employees at the manufacturing facilities are performing work that is critical to the integrity of the supply chain for our end users that provide essential goods and services. The layout of our manufacturing lines allows for social distancing,...

RESEARCH TRIANGLE PARK, N.C., April 08, 2020 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 10:00 a.m. ET. The conference is being conducted as a virtual conference.Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.About BioCryst PharmaceuticalsBioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930,...

STAMFORD, Conn., April 08, 2020 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the virtual 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 10:00 a.m. ET.A live webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.About Cara TherapeuticsCara Therapeutics...

DUBLIN, Ireland, April 08, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, at 11:20a.m. ET.The presentation will be webcast live and may be accessed by visiting the “Investors” section of the Company’s website under the “Events and Presentations” tab at www.nabriva.com. A replay of the webcast will be available for 90 days.About Nabriva Therapeutics plcNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development...

Not for distribution to U.S. Newswire Services or for dissemination in the United States.  Any failure to comply with this restriction may constitute a violation of U.S. securities laws.VANCOUVER, British Columbia, April 08, 2020 (GLOBE NEWSWIRE) — Search Minerals Inc. (TSXV: SMY) (“Search” or the “Company”) is pleased to report assay results from SILVER FOX, its fourth major mineralized zone in its Port Hope Simpson – St. Lewis Critical Rare Earth Element (“CREE”) District. Trenching/channelling (4 new channels in 2019), and mapping/prospecting indicate that the surface expression of this mineralized zone is up to 8.8m wide and 650m long. This surface expression is significantly longer, but thinner, than the surface expressions of the nearby and related FOXTROT and DEEP FOX Resources. The mineralization is similarly hosted by peralkaline...

Hoivatilat PlcStock exchange release8 April 2020 at 2 pm EETHoivatilat Plc changes its financial reporting practiceHoivatilat Plc (“Hoivatilat”) will change its financial reporting practice and only publish a half year financial report and a financial statements bulletin in the future. Hoivatilat will therefore not publish the business review for January – March 2020 on 6 May 2020 or the business review for January – September 2020 on 4 November 2020, as previously announced.Aureit Holding Oy (“Aureit Holding”) has acquired through a public tender offer more than 90 per cent of all the issued and outstanding shares and votes in Hoivatilat. Aureit Holding has on 15 January 2020 commenced mandatory redemption proceedings in respect of Hoivatilat’s minority shares by applying for arbitration proceedings to be...